Kashiv Specialty Pharmaceuticals (KSP) is a subsidiary of Kashiv Biosciences, formed to develop complex generics, innovative drug delivery platforms, and novel 505(b)(2) drugs.
Kashiv Specialty Pharmaceuticals operates from a 150,000 Sq. Ft. fully integrated state-of-the-art R&D & cGMP compliant manufacturing facility located in Bridgewater, New Jersey. It has approximately 80 employees with 70% holding a Masters or PhD degree involved in formulation development, analytical testing, and oral drug manufacturing.
KSP is a fully integrated pharmaceutical company with capabilities to develop and manufacture innovative medicines, next-generation drug delivery technologies and clinically differentiated specialty pharmaceutical products.
We are built on patient-focused innovation and development of advanced drug delivery platforms with application in a wide variety of molecules to improve their clinical activity.
We identify unmet medical needs in various therapeutic areas and develop effective, safe, and clinically differentiated medicines to improve the health outcome and quality of life for all patients.
Since the start of its operations in 2011, KSP under the leadership of top industry formulation scientists has developed several patented next generation oral drug delivery technologies, 15 high-value complex generic products successfully launched by a partner, and a proprietary clinical stage pipeline of five differentiated 505(b)(2) products targeting orphan and severe diseases. KSP has a growing pipeline of several new complex generics and new 505(b)(2) candidates undergoing feasibility testing and formulation development.
We are a People-Oriented
We are a fast-growing specialty pharmaceutical company providing an innovative environment and opportunities for professional growth.
Bridgewater, New Jersey
Kashiv Specialty Pharmaceuticals operates from a state-of-the-art 150,000 sq.ft. R&D and manufacturing facility with capabilities for the development of innovative platform technologies, specialty products, controlled substances (CII-V), and complex oral dosage forms. It is an FDA-registered site and complies fully with Local, State, and Federal Agencies, OSHA, DEA, EPA, and cGMP Standards.
cGMP Manufacturing Facility
Technicians operate a three-layer tablet press used for controlled release products
Corporate Headquarters and oral R&D and Manufacturing Site